Investigational Epcoritamab (DuoBody CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1…
Investigational Epcoritamab (DuoBody CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response…
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
— Phase 3 POD1UM-304 trial met primary endpoint of overall survival (OS)…
2025 Kia EV9 and Kia Sorento Named Winners by the Hispanic Motor Press
Kia EV9 named “Best EV of the Year” and Sorento named “Best…
Woxsen University’s School of Business achieves a higher ranking in the Business World B-School Rankings 2024
Ranked #11, Top Private B-schools in India, Business World Ranking 2024Ranked #20,…
MAIA Biotechnology Announces Expansion of Clinical Supply Agreement with Regeneron for Phase 2 Trial in Non-Small Cell Lung Cancer
Expansion of 2021 clinical supply agreement for Phase 2 clinical trial Next…
Wednesday Launches the World’s First Greens & Superfood Gummy
Wednesday is the first to launch a Greens & Superfood Gummy, combining…
Novo Nordisk A/S – share repurchase programme
Bagsværd, Denmark, 25 November 2024 – On 11 November 2024, Novo Nordisk initiated…
Combination of Eflornithine and Lomustine Demonstrates Clinically Meaningful Improvements in Overall Survival (OS) and Progression Free Survival (PFS) in Patients with Recurrent Astrocytoma, IDH Mutant Grade 3
November 22, 2024 11:00 ET | Source: Orbus Therapeutics, Inc. – OS…
Cytek Biosciences Named Overall BioTech Company of the Year in 2024 BioTech Breakthrough Awards Program
FREMONT, Calif., Nov. 19, 2024 (GLOBE NEWSWIRE) -- Cytek Biosciences, Inc. (Nasdaq:…